<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Based on the above considerations and continuing the investigations on EOs as effective antimicrobial agents [
 <xref rid="B10-molecules-23-02584" ref-type="bibr" class="xref">10</xref>,
 <xref rid="B18-molecules-23-02584" ref-type="bibr" class="xref">18</xref>,
 <xref rid="B19-molecules-23-02584" ref-type="bibr" class="xref">19</xref>,
 <xref rid="B20-molecules-23-02584" ref-type="bibr" class="xref">20</xref>,
 <xref rid="B21-molecules-23-02584" ref-type="bibr" class="xref">21</xref>,
 <xref rid="B22-molecules-23-02584" ref-type="bibr" class="xref">22</xref>,
 <xref rid="B23-molecules-23-02584" ref-type="bibr" class="xref">23</xref>], the main aim of this report was to evaluate the in-vitro activity of a chemically characterized commercial TTO, alone and in combination with different antimicrobials, against methicillin-susceptible 
 <italic class="italic">Staphylococus aureus</italic> (MSSA), methicillin-resistant 
 <italic class="italic">Staphylococus aureus</italic> (MRSA), 
 <italic class="italic">Escherichia coli</italic> and MDR Gram-negative bacteria including extended-spectrum beta lactamases (ESBLs) producer carbapenem-sensitive 
 <italic class="italic">Klebsiella pneumoniae</italic> (ESBL-CS-Kp), ESBL and carbapenem-resistant 
 <italic class="italic">K. pneumoniae</italic> (CR-Kp), carbapenem-resistant 
 <italic class="italic">Acinetobacter baumannii</italic> (CR-Ab) and carbapenem-resistant 
 <italic class="italic">Pseudomonas aeruginosa</italic> (CR-Pa). In addition, the antibacterial effectiveness of TTO in the VP against the abovementioned microorganisms was investigated.
</p>
